Literature DB >> 13189069

United States Public Health service cooperative investigation of antimicrobial therapy of tuberculosis, V. Report on thirty-two-week observations on combinations of isoniazid, streptomycin, and para-aminosalicylic acid.

F W MOUNT, S H FEREBEE.   

Abstract

Entities:  

Keywords:  NICOTINIC ACID ISOMERS/therapeutic use; PARA-AMINOSALICYLIC ACID/therapeutic use; STREPTOMYCIN/therapeutic use; TUBERCULOSIS, PULMONARY/therapy

Mesh：

Substances：

Year:  1954        PMID： 13189069     DOI： 10.1164/art.1954.70.3.521

Source DB:  PubMed          Journal:  Am Rev Tuberc        ISSN： 0096-0381


× No keyword cloud information.
  7 in total

1.  Combined drug treatment of tuberculosis. I. Prevention of emergence of mutant populations of tubercle bacilli resistant to both streptomycin and isoniazid in vitro.

Authors:  M L COHN; G MIDDLEBROOK; W F RUSSELL
Journal:  J Clin Invest       Date:  1959-08       Impact factor: 14.808

2.  VARIOUS combinations of isoniazid with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; seventh report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee.

Authors: 
Journal:  Br Med J       Date:  1955-02-19

3.  [Reasons for failures of chemotherapy in tuberculosis].

Authors:  H Sighart
Journal:  Beitr Klin Erforsch Tuberk Lungenkr       Date:  1968

4.  Antimicrobial therapy of pulmonary tuberculosis.

Authors:  W McDermott
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

5.  Management of tuberculosis in childhood.

Authors:  M J CARSON; R KOCH
Journal:  Calif Med       Date:  1956-10

6.  Bridging implementation, knowledge, and ambition gaps to eliminate tuberculosis in the United States and globally.

Authors:  Kenneth G Castro; Philip LoBue
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

7.  The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

Authors:  P R Donald; D P Parkin; H I Seifart; H S Schaaf; P D van Helden; C J Werely; F A Sirgel; A Venter; J S Maritz
Journal:  Eur J Clin Pharmacol       Date:  2007-05-16       Impact factor: 3.064
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.